bdnf

Member of the neurotrophin growth factor family that binds and activates TrkB and p75 neurotrophin receptors. Enhances the survival, growth and differentiation of neurons. BDNF expression is altered in neurodegenerative disorders such as Parkinson's and A

Cyclotraxin B acetate is an antagonist of TrkB receptors; inhibits BDNF-induced TrkB activity (IC50 = 0.30 nM). Allosterically alters TrkB receptor conformation but does not alter BDNF binding. Prevents BDNF-induced cold allodynia in mice. Also shown to exhibit putative anxiolytic properties in mice.

Antagonist of TrkB receptors; inhibits BDNF-induced TrkB activity (IC50 = 0.30 nM). Allosterically alters TrkB receptor conformation but does not alter BDNF binding. Prevents BDNF-induced cold allodynia in mice. Also shown to exhibit putative anxiolytic p

Orexin A (Hypocretin-1) (human, rat, mouse) acetate, a hypothalamic neuropeptide with analgesic abilities that penetrates the blood-brain barrier, acts as an OX1R agonist. It promotes the expression of BDNF and TH proteins within SH-SY5Y cells, showing both time- and dose-dependent responses. This compound is valuable for researching appetite control, neurodegenerative conditions, and the modulation of detrimental signaling [1] [2] [3].

Cyclotraxin B TFA, a cyclic peptide, serves as a highly potent and selective non-competitive inhibitor of TrkB, effectively impeding BDNF-triggered TrkB activity without altering BDNF binding affinity, evidenced by an IC50 of 0.30 nM. It is capable of crossing the blood-brain barrier, demonstrating analgesic and anxiolytic-like behavioral effects [1] [2] [3].